NasdaqGS:ARWRBiotechs
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses
Arrowhead Pharmaceuticals, Inc. reported its third-quarter 2026 results, with sales rising to US$75.25 million from US$27.77 million a year earlier, while net loss widened to US$194.28 million and loss per share increased to US$1.36 from US$1.26.
Over the first nine months of 2026, Arrowhead shifted from net income of US$22.12 million a year ago to a net loss of US$296.21 million despite generating more than US$400 million in sales, highlighting how rising expenses and reduced collaboration...